A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer (METRIX)

AbbVie

Status: Completed

Conditions: Non Small Cell Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT06068842

H24-281

Details and patient eligibility

About

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases of which 60% are non-squamous (NSQ). This study will evaluate the prevalence of mesenchymal epithelial transition (MET) overexpression (OE) in adult participants with advanced or metastatic NSQ NSCLC.

Archived tissue biopsies will be tested for MET OE and data from approximately 500 participants will be collected. No participants will be enrolled in this study.

Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the study will be approximately 15 months.

There is no additional burden for participants in this trial.

Enrollment: 579 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Previously consented and/or prospective collection of consent for research use of banked biological materials and clinical data.
• Confirmed advanced and/or metastatic non-squamous (NSQ) non-small cell lung cancer (NSCLC).
• Has formalin-fixed paraffin-embedded (FFPE) tissue collected since 2019.

Exclusion criteria

• Specimens collected before 2019.
• Insufficient specimen tissue for testing.
• Insufficient specimen quality (e.g., not 4-5 µm in thickness) which precludes testing.
• Adenosquamous and sarcomatous histologies of NSCLC.

Trial design

579 participants in 1 patient group

Participants Undergoing Chart Review

Description:

Participants treated for non small cell lung cancer undergoing chart review and retrospective mesenchymal epithelial transition (MET) overexpression (OE) testing of tissue biopsies.